One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented new research at the 82nd Scientific Sessions of the American Diabetes Association on attitudes and adoption of continuous glucose monitors (CGM) among people with type 2 diabetes (T2D).
Also Read: RxBIO Launches Neogen Plasma Skin Rejuvenation in the USA – Neogen Plasma Brings a Unique Solution
Participants in the mixed-method study shared an overwhelmingly positive reception and significant interest in continuous glucose monitoring. Ninety percent of respondents were familiar with CGM technology, and most were open to adoption. Their reasons for openness included valuing regular feedback, relief from blood glucose monitor (BGM) fingersticks, convenience, and improved diabetes management. Still, 83% had never tried CGM, mirroring national statistics for T2Ds, and a subset expressed concerns about insurance coverage and costs. Those not open to CGM adoption also cited cost concerns as well as lack of need or familiarity, inconvenience, and device user experience (e.g., pain, size).
Type 2 diabetes accounts for up to 95% of all incidences of diabetes (diagnosed and undiagnosed) in the United States—37.3 million people and counting. With approximately 2.4 million CGM users domestically, according to a 2021 market analysis by Seagrove Partners, the adoption rate across all diabetes types is comparatively low. However, up to 70% of CGM use is for type 1 diabetes (T1D); only 3-4% of the U.S. T2D population use CGM despite established benefits. Study results in the context of national statistics indicate advancements in device technology, reimbursement policy, and digital health interventions to increase health knowledge and motivation are warranted to better meet the needs and preferences of millions currently living with T2D.
“As a full-time CGM user, I firmly believe continuous health sensing technology should be accessible to everyone with diabetes,” said Jeff Dachis, CEO and founder of One Drop. “What I have found through my personal experience living with diabetes and building an industry-leading medical device and digital health startup is that people can begin to gain control of their health when they have access to actionable health data insights and understand what to do with it. We should be tearing down barriers to tools that help us all live healthier lives.”